ClinicalTrials.gg
CompletedNCT01103960Updated Jun 27, 2014Results posted

An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy

A Phase 3 interventional study of Telmisartan80mg+Amlodipine5mg and amlodipine 5mg in Hypertension, sponsored by Boehringer Ingelheim. Completed at 16 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.

Enrollment
44th of 74
324 · median 381
Started
2010
with 7 others
Phase 3
43 of 122
1 open now
Registered
55th of 122
by date

Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 44th largest by enrollment of the 74 interventional ones that give a count, is one of 8 that started in 2010, is one of 43 in phase 3, and was the 55th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Hypertension by Boehringer Ingelheim, or all of them as a file.
02

Study summary

The primary objectives of this trial is to demonstrate that the fixed-dose combination of telmisartan 80mg plus amlodipine 5mg (T80/A5) is superior to amlodipine 5mg (A5) in reducing seated trough diastolic blood pressure (DBP) at 8 weeks.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. diagnosis of essential hypertension
  2. failure to respond adequately to six weeks treatment with amlodipine 5 mg monotherapy
  3. provision of written

Exclusion criteria

Exclusion criteria:

  1. clinical conditions which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine for the planned duration of this trial (e.g. populations where labeling of either product recommends against its utilization)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
324 participants (actual)

Study arms

  • Experimental
    Telmisartan80mg+Amlodipine5mg

    combination therapy

    Drug: Telmisartan80mg+Amlodipine5mg

  • Active comparator
    amlodipine 5 mg

    Monotherapy

    Drug: amlodipine 5mg · Drug: Telmisartan80mg+Amlodipine 5mg

Interventions

  • DrugTelmisartan80mg+Amlodipine5mg

    combination therapy

  • DrugAmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    monotherapy

  • DrugTelmisartan80mg+Amlodipine 5mg

    combination therapy

06

What researchers measure

Primary outcomes

  1. Change From Baseline in DBP After 8 Weeks of Treatment

    Seated trough DBP after 8 weeks or last observation carried forward (LOCF). Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.

    Time frame: Baseline and 8 weeks

  2. Change From Baseline in DBP After 8 Weeks of Treatment in Chinese Patients

    Seated trough DBP after 8 weeks or LOCF in Chinese patients. Analysis will be adjusted for treatment and baseline measurement of endpoint.

    Time frame: Baseline and 8 weeks

Secondary outcomes

  1. Change From Baseline in SBP After 8 Weeks of Treatment

    Seated trough SBP after 8 weeks or LOCF. Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.

    Time frame: Baseline and 8 weeks

  2. DBP and SBP Control and Response After 8 Weeks of Treatment

    DBP control is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP \<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=10mmHg. SBP response is defined as SBP\<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=15mmHg.

    Time frame: Baseline and 8 weeks

  3. Number of Patients in Blood Pressure Categories Over Time

    BP optimal: SBP \<120 mmHg and DBP \<80 mmHg, BP normal: SBP \<130 mmHg and DBP \<85 mmHg but not optimal, BP high-normal: SBP \<140 mmHg and DBP \<90 mmHg but not normal. Grade 1 hypertension: SBP \<160 mmHg and DBP \<100 mmHg but not high-normal, Grade 2 hypertension: SBP \<180 mmHg and DBP \<110 mmHg but not grade 1, Grade 3 hypertension: SBP \>=180 mmHg or DBP \>=110 mmHg.

    Time frame: 8 weeks

  4. Change From Baseline in DBP After 4 Weeks of Treatment

    Seated trough DBP after 4 weeks.

    Time frame: Baseline and 4 weeks

  5. Change From Baseline in SBP After 4 Weeks of Treatment

    Seated trough SBP after 4 weeks.

    Time frame: Baseline and 4 weeks

  6. DBP and SBP Control and Response After 4 Weeks of Treatment

    DBP control is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP \<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=10mmHg. SBP response is defined as SBP\<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=15mmHg.

    Time frame: Baseline and 4 weeks

  7. Number of Patients in Blood Pressure Categories at 4 Weeks

    BP optimal: SBP \<120 mmHg and DBP \<80 mmHg, BP normal: SBP \<130 mmHg and DBP \<85 mmHg but not optimal, BP high-normal: SBP \<140 mmHg and DBP \<90 mmHg but not normal. Grade 1 hypertension: SBP \<160 mmHg and DBP \<100 mmHg but not high-normal, Grade 2 hypertension: SBP \<180 mmHg and DBP \<110 mmHg but not grade 1, Grade 3 hypertension: SBP \>=180 mmHg or DBP \>=110 mmHg.

    Time frame: 4 weeks

  8. Clinically Relevant Abnormalities for Physical Examination, Pulse Rate, Laboratory Parameters and ECG.

    Clinically relevant abnormalities for Physical examination, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.

    Time frame: From drug administration until end of treatment plus one day

07

Results

Posted Sep 20, 2012

Participant flow

Participant flow — Overall Study
MilestoneA5 AloneT80/A5
Started164160
Completed159158
Not completed52
Withdrew: Adverse event21
Withdrew: Withdrawal by subject21
Withdrew: Other10

Outcome measures

PrimaryChange From Baseline in DBP After 8 Weeks of Treatment

Seated trough DBP after 8 weeks or last observation carried forward (LOCF). Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.

Time frame:
Baseline and 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in DBP After 8 Weeks of Treatment
mmHgA5 AloneT80/A5
Change From Baseline in DBP After 8 Weeks of Treatment-10.19 ± 0.93-12.38 ± 0.95
Statistical analysis
  • A5 Alone vs T80/A5 · ANCOVA · p = 0.007 (This was the first step in the closed testing procedure of multiple endpoints. The p-value was \<0.05 so this test was considered confirmatory. Proceeding to the next step was allowed, testing the same endpoint in the subgroup of Chinese patients.) · Mean difference (final values): 2.1881 · 95% CI 0.6082 to 3.7681
PrimaryChange From Baseline in DBP After 8 Weeks of Treatment in Chinese Patients

Seated trough DBP after 8 weeks or LOCF in Chinese patients. Analysis will be adjusted for treatment and baseline measurement of endpoint.

Time frame:
Baseline and 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in DBP After 8 Weeks of Treatment in Chinese Patients
mmHgA5 AloneT80/A5
Change From Baseline in DBP After 8 Weeks of Treatment in Chinese Patients-8.85 ± 0.63-10.77 ± 0.64
Statistical analysis
  • A5 Alone vs T80/A5 · ANCOVA · p = 0.034 (This was the second step in the closed testing procedure of multiple endpoints. The p-value was again \<0.05 so this test was also considered confirmatory.) · Mean difference (final values): 1.9195 · 95% CI 0.1443 to 3.6947
SecondaryChange From Baseline in SBP After 8 Weeks of Treatment

Seated trough SBP after 8 weeks or LOCF. Analysis will be adjusted for treatment, country, and baseline measurement of endpoint.

Time frame:
Baseline and 8 weeks
Reported as:
Least squares mean · mmHg
Change From Baseline in SBP After 8 Weeks of Treatment
mmHgA5 AloneT80/A5
Change From Baseline in SBP After 8 Weeks of Treatment-11.66 ± 1.30-16.15 ± 1.33
Statistical analysis
  • A5 Alone vs T80/A5 · ANCOVA · p = <0.001 · Mean difference (final values): 4.4879 · 95% CI 2.2807 to 6.6950
SecondaryDBP and SBP Control and Response After 8 Weeks of Treatment

DBP control is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP \<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=10mmHg. SBP response is defined as SBP\<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=15mmHg.

Time frame:
Baseline and 8 weeks
Reported as:
Number · Number of participants
DBP and SBP Control and Response After 8 Weeks of Treatment
Number of participantsA5 AloneT80/A5
DBP control85112
SBP control100119
DBP response101124
SBP response120131
SecondaryNumber of Patients in Blood Pressure Categories Over Time

BP optimal: SBP \<120 mmHg and DBP \<80 mmHg, BP normal: SBP \<130 mmHg and DBP \<85 mmHg but not optimal, BP high-normal: SBP \<140 mmHg and DBP \<90 mmHg but not normal. Grade 1 hypertension: SBP \<160 mmHg and DBP \<100 mmHg but not high-normal, Grade 2 hypertension: SBP \<180 mmHg and DBP \<110 mmHg but not grade 1, Grade 3 hypertension: SBP \>=180 mmHg or DBP \>=110 mmHg.

Time frame:
8 weeks
Reported as:
Number · Number of participants
Number of Patients in Blood Pressure Categories Over Time
Number of participantsA5 AloneT80/A5
BP optimal711
BP normal3336
BP high-normal3253
Grade 1 hypertension6948
Grade 2 hypertension155
Grade 3 hypertension32
SecondaryChange From Baseline in DBP After 4 Weeks of Treatment

Seated trough DBP after 4 weeks.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · mmHg
Change From Baseline in DBP After 4 Weeks of Treatment
mmHgA5 AloneT80/A5
Change From Baseline in DBP After 4 Weeks of Treatment-7.51 ± 6.80-9.41 ± 7.26
SecondaryChange From Baseline in SBP After 4 Weeks of Treatment

Seated trough SBP after 4 weeks.

Time frame:
Baseline and 4 weeks
Reported as:
Mean · mmHg
Change From Baseline in SBP After 4 Weeks of Treatment
mmHgA5 AloneT80/A5
Change From Baseline in SBP After 4 Weeks of Treatment-8.19 ± 11.45-12.10 ± 11.68
SecondaryDBP and SBP Control and Response After 4 Weeks of Treatment

DBP control is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP \<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP \<90 mmHg or \<80 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=10mmHg. SBP response is defined as SBP\<140 mmHg or \<130 mmHg in patients with diabetes or renal impairment or a reduction from baseline \>=15mmHg.

Time frame:
Baseline and 4 weeks
Reported as:
Number · Number of participants
DBP and SBP Control and Response After 4 Weeks of Treatment
Number of participantsA5 AloneT80/A5
DBP control7195
SBP control91103
DBP response87108
SBP response108124
SecondaryNumber of Patients in Blood Pressure Categories at 4 Weeks

BP optimal: SBP \<120 mmHg and DBP \<80 mmHg, BP normal: SBP \<130 mmHg and DBP \<85 mmHg but not optimal, BP high-normal: SBP \<140 mmHg and DBP \<90 mmHg but not normal. Grade 1 hypertension: SBP \<160 mmHg and DBP \<100 mmHg but not high-normal, Grade 2 hypertension: SBP \<180 mmHg and DBP \<110 mmHg but not grade 1, Grade 3 hypertension: SBP \>=180 mmHg or DBP \>=110 mmHg.

Time frame:
4 weeks
Reported as:
Number · Number of participants
Number of Patients in Blood Pressure Categories at 4 Weeks
Number of participantsA5 AloneT80/A5
BP optimal17
BP normal2026
BP high-normal3544
Grade 1 hypertension8162
Grade 2 hypertension1715
Grade 3 hypertension51
SecondaryClinically Relevant Abnormalities for Physical Examination, Pulse Rate, Laboratory Parameters and ECG.

Clinically relevant abnormalities for Physical examination, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.

Time frame:
From drug administration until end of treatment plus one day
Reported as:
Number · participants
Clinically Relevant Abnormalities for Physical Examination, Pulse Rate, Laboratory Parameters and ECG.
participantsA5 AloneT80/A5
Atrial fibrilation01
Myocardial ischaemia10
Blood glucose increased14
Protein urine present21
Alanine aminotransferase increased01
Blood creatinine phosphokinase increased10
Blood creatinine increased01
Blood glucose abnormal11
Heart rate increased01

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A5 Alone—0/164 (0%)0/164 (0%)
T80/A5—0/160 (0%)0/160 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)A5 AloneT80/A5Total
Mean52.4 ± 9.752.4 ± 8.752.4 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)A5 AloneT80/A5Total
Female7178149
Male8877165
Diastolic blood pressure (DBP)
Diastolic blood pressure (DBP)(mmHg)A5 AloneT80/A5Total
Mean97.84 ± 6.4397.21 ± 5.4697.53 ± 5.97
Systolic blood pressure (SBP)
Systolic blood pressure (SBP)(mmHg)A5 AloneT80/A5Total
Mean146.27 ± 11.15146.44 ± 12.20146.35 ± 11.66
08

Study locations

16 sites
  • 1235.29.86001 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 1235.29.86004 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 1235.29.86006 Boehringer Ingelheim Investigational Site
    Changchun, China
  • 1235.29.86013 Boehringer Ingelheim Investigational Site
    Changsha, China
  • 1235.29.86014 Boehringer Ingelheim Investigational Site
    Guangzhou, China
  • 1235.29.86012 Boehringer Ingelheim Investigational Site
    Hangzhou, China
  • 1235.29.86002 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1235.29.86009 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1235.29.86010 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1235.29.86011 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1235.29.86007 Boehringer Ingelheim Investigational Site
    Shenyang, China
  • 1235.29.86008 Boehringer Ingelheim Investigational Site
    Tianjin, China
  • 1235.29.60017 Boehringer Ingelheim Investigational Site
    Johor, Malaysia
  • 1235.29.60016 Boehringer Ingelheim Investigational Site
    Kuala Lumpur, Malaysia
  • 1235.29.63018 Boehringer Ingelheim Investigational Site
    Metro Manila, Philippines
  • 1235.29.63019 Boehringer Ingelheim Investigational Site
    Quezon City, Philippines
09

References and documents

Publications

  • Zhu D, Gao P, Holtbruegge W, Huang C. A randomized, double-blind study to evaluate the efficacy and safety of a single-pill combination of telmisartan 80 mg/amlodipine 5 mg versus amlodipine 5 mg in hypertensive Asian patients. J Int Med Res. 2014 Feb;42(1):52-66. doi: 10.1177/0300060513503756. Epub 2014 Jan 3. PubMed 24391142 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010 and a primary completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2010
First posted
Apr 15, 2010
Start
Jul 2010
Primary completionActual
Aug 2011
Results first posted
Sep 20, 2012
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01103960
Responsible party
Sponsor
First posted
Apr 15, 2010
Start date
Jul 2010
Primary completion
Aug 2011
Results posted
Sep 20, 2012
Last update
Jun 27, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion